StockNews.AI
KNSA
StockNews.AI
180 days

Kiniksa Pharmaceuticals to Report Fourth Quarter and Full Year 2024 Financial Results on February 25, 2025

1. Kiniksa announces Q4 and full year 2024 financial results call. 2. Conference call scheduled for Feb 25, 2025, at 8:30 a.m. ET. 3. Live webcast and telephone registration available on company website. 4. Portfolio execution and cardiovascular therapies focus highlighted by management.

3m saved
Insight
Article

FAQ

Why Neutral?

The announcement is a standard earnings call notification; historical earnings announcements cause volatility only after results are reported, not merely on schedule.

How important is it?

Earnings call announcements are important events; however, without new financial data, the impact remains moderate until the results are disclosed.

Why Short Term?

Earnings calls typically affect short-term price movements as results trigger immediate investor reactions.

Related Companies

February 20, 2025 16:01 ET  | Source: Kiniksa Pharmaceuticals, Ltd. LONDON, Feb. 20, 2025 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) announced today that it will host a conference call and live webcast on Tuesday, February 25, 2025 at 8:30 a.m. Eastern Time to report its fourth quarter and full year 2024 financial results and recent portfolio execution. A live webcast will be accessible through the Investors & Media section of the company’s website at www.kiniksa.com. Individuals interested in participating in the call via telephone may register here. Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number along with a unique passcode and registrant ID that can be used to access the call. A replay of the event will also be available on Kiniksa’s website within approximately 48 hours after the event. About KiniksaKiniksa is a biopharmaceutical company dedicated to improving the lives of patients suffering from debilitating diseases by discovering, acquiring, developing, and commercializing novel therapies for diseases with unmet need, with a focus on cardiovascular indications. Kiniksa’s portfolio assets are based on strong biologic rationale or validated mechanisms and offer the potential for differentiation. For more information, please visit www.kiniksa.com. Every Second Counts! ® Kiniksa Investor ContactJonathan Kirshenbaum(781) 829-3949jkirshenbaum@kiniksa.com Kiniksa Media ContactTyler Gagnon (781) 431-9100tgagnon@kiniksa.com

Related News